Time for reform in the drug-development process.
Fricker
Janet
J
D000970:Antineoplastic Agents / Q000191:economics / Q000494:pharmacology / Q000592:standards; D001499:Bayes Theorem; D001549:Benzamides; D017321:Clinical Trials, Phase I as Topic / Q000191:economics; D017322:Clinical Trials, Phase II as Topic / Q000191:economics; D017277:Drug Approval / Q000458:organization & administration; D015195:Drug Design; D005060:Europe; D019317:Evidence-Based Medicine; D006801:Humans; D000068877:Imatinib Mesylate; D010879:Piperazines; D011743:Pyrimidines; D012107:Research Design; D006113:United Kingdom; D014481:United States; D014486:United States Food and Drug Administration
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate